OneChain Immunotherapeutics

OneChain Immunotherapeutics is a spin-off company from the Josep Carreras Leukaemia Research Institute (IJC) and ICREA. The company aims to develop immunotherapies against haematological neoplasms using Gammadelta T cell therapies and generate new CAR-T candidates against different antigens. The first candidate is a CAR-CD1a for co-T-ALL. The company has the aim to develop CAR–T therapies using an allogenic platform based on a novel and efficient method for a selective generation of human cytotoxic Vδ1+ T cells.

  • CEO: Jorge Alemany
  • CSO & Founder: Pablo Menéndez
  • Location: Barcelona
  • Website: onechaintx.com